Please use this identifier to cite or link to this item:
|Title:||Identification of novel anti-pathogenic compounds against pseudomonas aeruginosa through drug repurposing||Authors:||Tan, Casandra Ai Zhu||Keywords:||DRNTU::Science||Issue Date:||2017||Abstract:||Biofilm formations have cause undesirable consequences because they are less susceptible to antimicrobial treatments and are protected from host immune responses. Despite this, pharmaceutical industry has produced very few novel antibiotics. Thus, there is a need for development of new drugs to eradicate biofilms. A promising approach is to repurpose drugs originally produced for other purposes for anti-pathogenic activity, as it circumvents the high cost and time associated with traditional de novo drug discovery. The aim of this study was to repurpose drugs from a library of 1,600 compounds as anti-pathogenic drugs against Pseudomonas aeruginosa via microtiter plate-based biofilm formation assay. Nisoldipine, a calcium channel blocker, was confirmed as a potential quorum sensing inhibitor because it showed inhibition of lasB expression in Pseudomonas aeruginosa (IC50 = 69.31 M) when screened against quorum sensing reporter strains. Nisoldipine also affected various virulence factors, including slight reduction in elastase activity, 20% increase in rhamnolipid production, 7% increase in swarming motility and inhibition of biofilm formation upon combinatory treatment with antibiotics. This is the first documentation indicating nisoldipine with some anti-pathogenic activities. Although results achieved suggested that nisoldipine might not be a promising compound, drug repurposing persists as a strategic approach for drug development against biofilms.||URI:||http://hdl.handle.net/10356/70519||Rights:||Nanyang Technological University||Fulltext Permission:||restricted||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SBS Student Reports (FYP/IA/PA/PI)|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.